As the Asian markets navigate a complex landscape shaped by geopolitical developments and economic fluctuations, investors are increasingly focused on identifying stocks that may be undervalued relative to their potential. In this environment, a good stock is often characterized by strong fundamentals and resilience to external pressures, offering opportunities for those seeking value in an ever-evolving market.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) |
HK$462.00 |
HK$893.91 |
48.3% |
| Shenzhen Clou Electronics (SZSE:002121) |
CN¥8.28 |
CN¥16.47 |
49.7% |
| Risen EnergyLtd (SZSE:300118) |
CN¥14.00 |
CN¥27.11 |
48.4% |
| Pan-United (SGX:P52) |
SGD1.50 |
SGD2.93 |
48.9% |
| NTT DC REIT (SGX:NTDU) |
US$0.98 |
US$1.94 |
49.6% |
| Moshi Moshi Retail Corporation (SET:MOSHI) |
THB36.75 |
THB72.59 |
49.4% |
| Loncin Motor (SHSE:603766) |
CN¥13.05 |
CN¥25.54 |
48.9% |
| EVE Energy (SZSE:300014) |
CN¥63.68 |
CN¥123.23 |
48.3% |
| APR (KOSE:A278470) |
₩395500.00 |
₩768801.80 |
48.6% |
| AcrobiosystemsLtd (SZSE:301080) |
CN¥40.55 |
CN¥78.64 |
48.4% |
We'll examine a selection from our screener results.
Innovent Biologics
Overview:Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, Europe, and other international markets with a market cap of HK$144.88 billion.
Operations:The company's revenue primarily comes from its biotechnology segment, generating CN¥13.04 billion.
Estimated Discount To Fair Value:41.2%
Innovent Biologics is trading at HK$83.35, significantly below its estimated future cash flow value of HK$141.82, suggesting it may be undervalued based on cash flows. Despite recent insider selling, Innovent's profitability and revenue growth outpace the Hong Kong market. The strategic alliance with Pfizer could enhance long-term cash flows through a US$650 million upfront payment and potential milestone payments up to US$10.5 billion, bolstering its financial position amidst strong earnings growth forecasts.
Akeso
Overview:Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of approximately HK$108.79 billion.
Operations:The company's revenue segment primarily consists of CN¥3.06 billion from the research, development, production, and sale of biopharmaceutical products.
Estimated Discount To Fair Value:37.5%
Akeso is trading at HK$118.10, well below its estimated future cash flow value of HK$188.82, indicating potential undervaluation. The company's earnings are projected to grow 60.63% annually, with revenue expected to increase by 27.1% per year, surpassing the Hong Kong market's growth rate of 8.7%. Despite a net loss in the previous year, Akeso's innovative therapies and strategic advancements position it for profitability within three years, potentially enhancing its financial outlook significantly.
Dajin Heavy IndustryLtd
Overview:Dajin Heavy Industry Co., Ltd. manufactures and sells wind and photovoltaic power generation equipment in China and internationally, with a market cap of CN¥52.90 billion.
Operations:Revenue Segments (in millions of CN¥): Wind power generation equipment: 8,500; Photovoltaic power generation equipment: 3,200.
Estimated Discount To Fair Value:47.7%
Dajin Heavy Industry Ltd. is trading at CN¥72.99, significantly below its estimated future cash flow value of CN¥139.64, reflecting potential undervaluation. The company reported robust earnings growth of 100.5% over the past year, with forecasts predicting annual profit and revenue increases of 34.2% and 32.7%, respectively—outpacing the Chinese market averages. Recent follow-on equity offerings totaling HK$6.64 billion may impact valuation but underscore strategic expansion efforts in a competitive industry landscape.
Summing It All Up
-
Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 184 companies by clicking here.
-
Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
-
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Interested In Other Possibilities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1801 SEHK:9926 and SZSE:002487.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
